The effect of α-synuclein on gliosis and IL-1α, TNFα, IFNγ, TGFβ expression in murine brain

Pharmacological Reports

Volumn 69, Issue 2, 2017, Pages 242-251

  Sznejder Pachołek, Anna ^a   Joniec Maciejak, Ilona ^a   Wawer, Adriana ^a   Ciesielska, Agnieszka ^b   Mirowska Guzel, Dagmara ^a,c  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Alpha synuclein; Cytokines; Gliosis; Neuroinflammation; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; GAMMA INTERFERON; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 1ALPHA; MESSENGER RNA; MONOMER; PROTEIN; PROTEIN IBA1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; DOPAMINE; SNCA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GLIOSIS; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA PARS COMPACTA; WESTERN BLOTTING; ANIMAL; ASTROCYTE; BRAIN; C57BL MOUSE; HUMAN; METABOLISM; PARKINSON DISEASE;

ALPHA-SYNUCLEIN; ANIMALS; ASTROCYTES; BRAIN; DOPAMINE; DOPAMINERGIC NEURONS; GLIOSIS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1ALPHA; MALE; MICE; MICE, INBRED C57BL; MICROGLIA; PARKINSON DISEASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85010424593     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2016.11.003     Document Type: Article

References (44)

1. [1] Uversky, V.N., Eliezer, D., Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci. 10:5 (2009), 483–499.
2. [2] Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:5321 (1997), 2045–2047.
3. [3] Ltic, S., Perovic, M., Mladenovic, A., Raicevic, N., Ruzdijic, S., Rakic, L., et al. Alpha-synuclein is expressed in different tissues during human fetal development. J Mol Neurosci 22:3 (2004), 199–204.
4. [4] Crews, L., Tsigelny, I., Hashimoto, M., Masliah, E., Role of synucleins in Alzheimer's disease. Neurotox Res 16:3 (2009), 306–317.
5. [5] Gardai, S.J., Mao, W., Schule, B., Babcock, M., Schoebel, S., Lorenzana, C., et al. Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One, 8(8), 2013, e71634.
6. [6] Lee, S.J., Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Mol Neurosci 34:1 (2008), 17–22.
7. [7] Aloisi, F., Immune function of microglia. Glia 36:2 (2001), 165–179.
8. [8] Dexter, D.T., Jenner, P., Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62 (2013), 132–144.
9. [9] Mirza, B., Hadberg, H., Thomsen, P., Moos, T., The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease. Neuroscience 95:2 (2000), 425–432.
10. [10] Wu, D.C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:5 (2002), 1763–1771.
11. [11] Reynolds, A.D., Glanzer, J.G., Kadiu, I., Ricardo-Dukelow, M., Chaudhuri, A., Ciborowski, P., et al. Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem 104:6 (2008), 1504–1525.
12. [12] Beraud, D., Hathaway, H.A., Trecki, J., Chasovskikh, S., Johnson, D.A., Johnson, J.A., et al. Microglial activation and antioxidant responses induced by the Parkinson's disease protein alpha-synuclein. J Neuroimmune Pharmacol 8:1 (2013), 94–117.
13. [13] Zhang, W., Wang, T., Pei, Z., Miller, D.S., Wu, X., Block, M.L., et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19:6 (2005), 533–542.
14. [14] Theodore, S., Cao, S., McLean, P.J., Standaert, D.G., Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol 67:12 (2008), 1149–1158.
15. [15] Sacino, A.N., Brooks, M., McKinney, A.B., Thomas, M.A., Shaw, G., Golde, T.E., et al. Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J Neurosci 34:37 (2014), 12368–12378.
16. [16] Breydo, L., Wu, J.W., Uversky, V.N., Alpha-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta 1822:2 (2012), 261–285.
17. [17] Codolo, G., Plotegher, N., Pozzobon, T., Brucale, M., Tessari, I., Bubacco, L., et al. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One, 8(1), 2013, e55375.
18. [18] Gruol, D.L., Nelson, T.E., Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 15:3 (1997), 307–339.
19. [19] Bessler, H., Djaldetti, R., Salman, H., Bergman, M., Djaldetti, M., IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother 53:3 (1999), 141–145.
20. [20] Brodacki, B., Staszewski, J., Toczylowska, B., Kozlowska, E., Drela, N., Chalimoniuk, M., et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 441:2 (2008), 158–162.
21. [21] Trembleau, S., Germann, T., Gately, M.K., Adorini, L., The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 16:8 (1995), 383–386.
22. [22] Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., Nagatsu, T., Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 211:1 (1996), 13–16.
23. [23] Niranjan, R., The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes. Mol Neurobiol 49:1 (2014), 28–38.
24. [24] Halliday, G.M., Stevens, C.H., Glia: initiators and progressors of pathology in Parkinson's disease. Mov Disord 26:1 (2011), 6–17.
25. [25] Tong, J., Ang, L.C., Williams, B., Furukawa, Y., Fitzmaurice, P., Guttman, M., et al. Low levels of astroglial markers in Parkinson's disease: relationship to alpha-synuclein accumulation. Neurobiol Dis 82 (2015), 243–253.
26. [26] Recasens, A., Dehay, B., Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat, 8, 2014, 159.
27. [27] Wawer, A., Joniec-Maciejak, I., Sznejder-Pacholek, A., Schwenkgrub, J., Ciesielska, A., Mirowska-Guzel, D., Exogenous alpha-synuclein monomers alter dopamine metabolism in murine brain. Neurochem Res 41:8 (2016), 2102–2109.
28. [28] Franklin, Keith B.J., Paxinos, George, The mouse brain in stereotaxic coordinates. 2001, Academic Press, San Diego, CA.
29. [29] Ciesielska, A., Joniec, I., Kurkowska-Jastrzebska, I., Cudna, A., Przybylkowski, A., Czlonkowska, A., et al. The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease. Inflamm Res 58:11 (2009), 747–753.
30. [30] Pfaffl, M.W., A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res, 29(9), 2001, e45.
31. [31] Colton, C., Wilcock, D.M., Assessing activation states in microglia. CNS Neurol Disord Drug Targets 9:2 (2010), 174–191.
32. [32] Ouchi, Y., Yoshikawa, E., Sekine, Y., Futatsubashi, M., Kanno, T., Ogusu, T., et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57:2 (2005), 168–175.
33. [33] Ouchi, Y., Yagi, S., Yokokura, M., Sakamoto, M., Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 15:Suppl. 3 (2009), S200–4.
34. [34] Bartels, A.L., Leenders, K.L., Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov Disord 22:13 (2007), 1852–1856.
35. [35] Knott, C., Wilkin, G.P., Stern, G., Astrocytes and microglia in the substantia nigra and caudate-putamen in Parkinson's disease. Parkinsonism Relat Disord 5:3 (1999), 115–122.
36. [36] Kurz, A., May, C., Schmidt, O., Muller, T., Stephan, C., Meyer, H.E., et al. A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP. J Neural Transm 119:3 (2012), 297–312.
37. [37] Tong, J., Wong, H., Guttman, M., Ang, L.C., Forno, L.S., Shimadzu, M., et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 133:Pt 1 (2010), 172–188.
38. [38] Nagatsu, T., Mogi, M., Ichinose, H., Togari, A., Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl 60 (2000), 277–290.
39. [39] Hebert, G., Mingam, R., Arsaut, J., Dantzer, R., Demotes-Mainard, J., Cellular distribution of interleukin-1alpha-immunoreactivity after MPTP intoxication in mice. Brain Res Mol Brain Res 138:2 (2005), 156–163.
40. [40] McGeer, P.L., Kawamata, T., Walker, D.G., Akiyama, H., Tooyama, I., McGeer, E.G., Microglia in degenerative neurological disease. Glia 7:1 (1993), 84–92.
41. [41] McGeer, P.L., Itagaki, S., Boyes, B.E., McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:8 (1988), 1285–1291.
42. [42] Jensen, M.B., Hegelund, I.V., Lomholt, N.D., Finsen, B., Owens, T., IFNgamma enhances microglial reactions to hippocampal axonal degeneration. J Neurosci 20:10 (2000), 3612–3621.
43. [43] Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359:6397 (1992), 693–699.
44. [44] Gomes, F.C., Sousa Vde, O., Romao, L., Emerging roles for TGF-beta1 in nervous system development. Int J Dev Neurosci 23:5 (2005), 413–424.